SCHEMBL1315577

SCHEMBL1315577

CC(C)(C)OC(=O)c1ccc(Oc2ccccc2)cc1NC(=O)c1cc(N2CCCCC2)ccc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 1/20 0.43
NTRK1 P04629 1/20 0.42
RXFP1 Q9HBX9 1/20 0.39
CSF1R P07333 1/20 0.38
PNLIP P16233 1/20 0.38
STK39 Q9UEW8 2/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
MAPT P10636 3/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GFER P55789 2/20 0.38
AHR P35869 1/20 0.38
ACHE P22303 1/20 0.38
BACE1 P56817 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
GAA P10253 2/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12118021 0.91 MAPT (0.44) SIRT6NTRK1RXFP1CSF1RKEAP1
SCHEMBL1316626 0.88 SIRT6 (0.45) SIRT6NTRK1RXFP1CSF1RPNLIP
SCHEMBL1316253 0.87 HDAC1 (0.44) RXFP1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1316431 0.86 LRRK2 (0.55)
SCHEMBL12118023 0.85 HTR6 (0.43) RXFP1CSF1RMAPTNPC1RAB9A
SCHEMBL1316896 0.82 MAPT (0.42) RXFP1CSF1RMAPTNPC1RAB9A
SCHEMBL1319038 0.81 RXFP1 (0.47) RXFP1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1316071 0.81 BACE1 (0.44) RXFP1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1316838 0.81 HDAC3 (0.44) MAPTMAPK1NPSR1LMNA
SCHEMBL1319258 0.80 HDAC1 (0.47) PNLIPSTK39GFERTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102333757-B N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD 2014-11-26 CN disclosed
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
EP-2385036-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2011-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF COL14A1, COL2A1, COL1A1 SIRT6 1009/4885NTRK1 4703/4885RXFP1 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.